JP2002540383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002540383A5 JP2002540383A5 JP2000595161A JP2000595161A JP2002540383A5 JP 2002540383 A5 JP2002540383 A5 JP 2002540383A5 JP 2000595161 A JP2000595161 A JP 2000595161A JP 2000595161 A JP2000595161 A JP 2000595161A JP 2002540383 A5 JP2002540383 A5 JP 2002540383A5
- Authority
- JP
- Japan
- Prior art keywords
- species
- forming
- binding
- fibril
- article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894007 species Species 0.000 description 162
- 238000000034 method Methods 0.000 description 110
- 230000027455 binding Effects 0.000 description 106
- 239000002245 particle Substances 0.000 description 70
- 230000004770 neurodegeneration Effects 0.000 description 59
- 208000015122 neurodegenerative disease Diseases 0.000 description 59
- 239000000523 sample Substances 0.000 description 44
- 239000000203 mixture Substances 0.000 description 29
- 239000013545 self-assembled monolayer Substances 0.000 description 29
- 239000002094 self assembled monolayer Substances 0.000 description 26
- 238000004220 aggregation Methods 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000011664 signaling Effects 0.000 description 10
- 239000000084 colloidal system Substances 0.000 description 8
- 239000013522 chelant Substances 0.000 description 7
- 230000000626 neurodegenerative effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000004523 agglutinating effect Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- -1 carboxylate salt Chemical class 0.000 description 3
- 238000000835 electrochemical detection Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical group [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11712699P | 1999-01-25 | 1999-01-25 | |
| US60/117,126 | 1999-01-25 | ||
| US13228899P | 1999-05-03 | 1999-05-03 | |
| US60/132,288 | 1999-05-03 | ||
| US15593799P | 1999-09-24 | 1999-09-24 | |
| US60/155,937 | 1999-09-24 | ||
| PCT/US2000/001997 WO2000043791A2 (en) | 1999-01-25 | 2000-01-25 | Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012161791A Division JP2012230124A (ja) | 1999-01-25 | 2012-07-20 | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002540383A JP2002540383A (ja) | 2002-11-26 |
| JP2002540383A5 true JP2002540383A5 (enExample) | 2007-03-22 |
| JP5122705B2 JP5122705B2 (ja) | 2013-01-16 |
Family
ID=27381935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000595161A Expired - Fee Related JP5122705B2 (ja) | 1999-01-25 | 2000-01-25 | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
| JP2012161791A Pending JP2012230124A (ja) | 1999-01-25 | 2012-07-20 | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012161791A Pending JP2012230124A (ja) | 1999-01-25 | 2012-07-20 | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1169646A2 (enExample) |
| JP (2) | JP5122705B2 (enExample) |
| AU (1) | AU3474100A (enExample) |
| CA (1) | CA2361013A1 (enExample) |
| WO (1) | WO2000043791A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413884A1 (en) * | 2000-06-23 | 2002-01-03 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of protein aggregation |
| AU2002216614A1 (en) | 2000-10-03 | 2002-04-15 | Minerva Biotechnologies Corporation | Electronic detection of interaction based on the interruption of flow |
| EP1336104B1 (en) | 2000-11-01 | 2009-03-25 | Minerva Biotechnologies Corporation | Proteomics based drug comparison methods |
| EP1348034B1 (en) * | 2000-11-15 | 2016-07-20 | Minerva Biotechnologies Corporation | Oligonucleotide identifiers |
| US7700715B2 (en) | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| US20030044843A1 (en) * | 2001-01-09 | 2003-03-06 | Mitsubishi Pharma Corporation | Novel proteome analysis method and devices therefor |
| US20060051741A1 (en) | 2002-10-04 | 2006-03-09 | Protosera Inc. | Plate for mass spectrometry, process for preparing the same and use thereof |
| US20050026165A1 (en) | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| AU2002320045B2 (en) | 2001-05-31 | 2008-05-08 | Adlyfe, Inc. | Misfolded protein sensor method |
| EP1425016B1 (en) | 2001-09-05 | 2010-06-02 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| JP2007531505A (ja) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | 癌（ｍｕｃ１）の診断および治療のための技術および組成物 |
| AU2003300371A1 (en) | 2002-12-20 | 2004-07-22 | Minerva Biotechnologies Corporation | Optical devices and methods involving nanoparticles |
| ES2398394T3 (es) | 2003-08-13 | 2013-03-15 | Novartis Vaccines And Diagnostics, Inc. | Reactivos peptídicos específicos de prión |
| DE602005016537D1 (de) | 2004-03-31 | 2009-10-22 | Anges Mg Inc | Testverfahren zur identifizierung eines kandidatenarzneistoffs |
| DE102004040119A1 (de) * | 2004-08-18 | 2006-04-27 | Heinrich-Heine-Universität Düsseldorf | Mittel zur Therapie und Prävention von Prionenerkrankungen |
| US20090130774A1 (en) * | 2005-01-13 | 2009-05-21 | David Peretz | Elisa assays using prion-specific peptide reagents |
| EP1853915B1 (en) | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| WO2007030804A1 (en) | 2005-09-09 | 2007-03-15 | Novartis Ag | Prion-specific peptoid reagents |
| JP5097206B2 (ja) | 2006-07-28 | 2012-12-12 | エイディーライフ インコーポレイティッド | 診断および治療のためのペプチドプローブ |
| AU2009246397B2 (en) | 2008-05-13 | 2013-01-17 | University Of Kansas | Metal abstraction peptide (MAP) tag and associated methods |
| KR20160017117A (ko) | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| WO2012017739A1 (ja) * | 2010-07-31 | 2012-02-09 | エレコン科学株式会社 | アミロイドアッセイ装置およびアミロイドアッセイ方法 |
| EP4086338A1 (en) | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| KR101352849B1 (ko) * | 2012-01-03 | 2014-01-21 | 주식회사 나노엔텍 | 멀티머-형성 폴리펩타이드의 멀티머형을 분별 검출하는 방법 |
| WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
| JP2016520846A (ja) * | 2013-06-06 | 2016-07-14 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 多量体の標的分子の検出に対する粒子ベースの試験において凝集を防ぐ試薬、方法及び装置 |
| EP3256494A4 (en) | 2015-02-10 | 2018-12-05 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| JP6630972B2 (ja) * | 2015-03-24 | 2020-01-15 | 学校法人甲南学園 | アミロイドβペプチドを電気化学的に測定するためのバイオセンサ |
| WO2017138696A1 (ko) * | 2016-02-12 | 2017-08-17 | 주식회사 캔티스 | 단백질 응집형의 검출 방법, 전기화학적 검출 키트 및 이를 이용한 비정상 단백질 응집 관련 질병의 진단 방법 및 전기화학적 진단 키트 |
| US11167283B2 (en) | 2018-05-04 | 2021-11-09 | University Of South Carolina | Dot blot box and use thereof |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CA3248038A1 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8417301D0 (en) * | 1984-07-06 | 1984-08-08 | Serono Diagnostics Ltd | Assay |
| US5705402A (en) * | 1988-11-03 | 1998-01-06 | Igen International, Inc. | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| GB9105031D0 (en) * | 1991-03-09 | 1991-04-24 | Fisons Plc | Processing analytical reagents |
| AU5358494A (en) | 1992-10-13 | 1994-05-09 | Duke University | Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein |
| WO1994010569A1 (en) * | 1992-10-26 | 1994-05-11 | Schenk Dale B | METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE |
| AU690092B2 (en) * | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| TW239881B (enExample) * | 1992-12-22 | 1995-02-01 | Sienna Biotech Inc | |
| EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| JPH06289020A (ja) * | 1993-04-06 | 1994-10-18 | Teijin Ltd | 歯槽骨由来タンパクの測定方法 |
| DE4430023A1 (de) * | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Elektrochemischer Sensor |
| SE9403245D0 (sv) * | 1994-09-26 | 1994-09-26 | Pharmacia Biosensor Ab | Improvements relating to bilayer lipid membranes |
| US6207369B1 (en) * | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
| EP1416280A3 (en) * | 1995-09-14 | 2005-08-10 | The Regents of the University of California | Antibodies specific for native PrPsc |
| JPH09275214A (ja) * | 1996-04-08 | 1997-10-21 | Hitachi Ltd | 微少電荷制御素子及びその作製法 |
| WO1998029727A2 (en) * | 1996-12-31 | 1998-07-09 | Stephon, Robert, L. | Microsphere-enhanced immunoassay for the detection of veterinary diseases |
| US6306584B1 (en) * | 1997-01-21 | 2001-10-23 | President And Fellows Of Harvard College | Electronic-property probing of biological molecules at surfaces |
| JPH10204350A (ja) * | 1997-01-27 | 1998-08-04 | Seiko Epson Corp | インクとインクジェットヘッドと印刷装置と配線基板 |
| JPH10217457A (ja) * | 1997-02-04 | 1998-08-18 | Seiko Epson Corp | インクジェットヘッドとその製造方法 |
| EP0861900A1 (en) | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
| EP0865078A1 (en) * | 1997-03-13 | 1998-09-16 | Hitachi Europe Limited | Method of depositing nanometre scale particles |
| US5998224A (en) * | 1997-05-16 | 1999-12-07 | Abbott Laboratories | Magnetically assisted binding assays utilizing a magnetically responsive reagent |
| EP0887645A1 (en) * | 1997-06-23 | 1998-12-30 | C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa | Procedure and instrumentation for the ultrasensitive detection of prions, prion binding biomolecules and other biomolecules |
| SG75126A1 (en) | 1997-06-23 | 2000-09-19 | Gen Electric | Electrochemical sensor for detection of chlorine in phosgene |
-
2000
- 2000-01-25 JP JP2000595161A patent/JP5122705B2/ja not_active Expired - Fee Related
- 2000-01-25 CA CA002361013A patent/CA2361013A1/en not_active Abandoned
- 2000-01-25 EP EP00913266A patent/EP1169646A2/en not_active Withdrawn
- 2000-01-25 AU AU34741/00A patent/AU3474100A/en not_active Abandoned
- 2000-01-25 WO PCT/US2000/001997 patent/WO2000043791A2/en not_active Ceased
-
2012
- 2012-07-20 JP JP2012161791A patent/JP2012230124A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4516273B2 (ja) | オリゴヌクレオチド識別子 | |
| JP2004526124A5 (enExample) | ||
| CA2423630C (en) | Magnetic in situ dilution | |
| JP5122705B2 (ja) | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 | |
| JP6662797B2 (ja) | タンパク質凝集の迅速且つ高感度の検出 | |
| Xia et al. | Design of electrochemical biosensors with peptide probes as the receptors of targets and the inducers of gold nanoparticles assembly on electrode surface | |
| US20050112607A1 (en) | Rapid and sensitive detection of protein aggregation | |
| JP2004512497A5 (enExample) | ||
| JP4335526B2 (ja) | コロイド構造体および非コロイド構造体による結合スピーシーズの検出 | |
| KR101395398B1 (ko) | 바이러스-마이크로비드 복합체 및 이의 용도 | |
| JP2008058285A (ja) | 生体関連物質の検出方法 | |
| US20050064446A1 (en) | Detection of binding species with colloidal and non-colloidal structures | |
| JP2010002393A (ja) | 標的物質の検出方法 | |
| WO2002001225A2 (en) | Tandem signaling assay | |
| AU2012202818A1 (en) | Detection of binding species with colloidal and non-colloidal structures |